Polyrizon Regains Compliance with Nasdaq Listing Requirements
Polyrizon (Nasdaq: PLRZ), a biotechnology company focused on intranasal product development, has successfully regained compliance with all Nasdaq listing requirements. The company received formal confirmation from the Nasdaq Hearings Panel's Hearings Advisor on August 13, 2025, confirming its compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
The confirmation satisfies all previously outlined conditions by the Nasdaq Hearings Panel in their July 9, 2025 decision. As a result, Polyrizon will maintain its listing and continue trading on the Nasdaq Capital Market under the ticker symbol "PLRZ".
Polyrizon (Nasdaq: PLRZ), una società biotecnologica specializzata nello sviluppo di prodotti intranasali, ha nuovamente ottenuto la conformità a tutti i requisiti di quotazione del Nasdaq. La società ha ricevuto conferma formale dall'advisor per le udienze del Nasdaq Hearings Panel il 13 agosto 2025, che attesta il rispetto del requisito relativo al prezzo minimo per azione previsto dalla Nasdaq Listing Rule 5550(a)(2).
Questa conferma soddisfa tutte le condizioni precedentemente indicate dal Nasdaq Hearings Panel nella decisione del 9 luglio 2025. Di conseguenza, Polyrizon manterrà la propria quotazione e continuerà a essere negoziata sul Nasdaq Capital Market con il simbolo "PLRZ".
Polyrizon (Nasdaq: PLRZ), una compañía biotecnológica centrada en el desarrollo de productos intranasales, ha recuperado con éxito el cumplimiento de todos los requisitos de cotización del Nasdaq. La empresa recibió la confirmación formal del asesor de audiencias del Nasdaq Hearings Panel el 13 de agosto de 2025, que certifica su cumplimiento del requisito de precio mínimo según la Nasdaq Listing Rule 5550(a)(2).
Dicha confirmación satisface todas las condiciones establecidas anteriormente por el Nasdaq Hearings Panel en su decisión del 9 de julio de 2025. En consecuencia, Polyrizon mantendrá su cotización y seguirá negociándose en el Nasdaq Capital Market bajo el símbolo "PLRZ".
Polyrizon (Nasdaq: PLRZ)는 비강 투여 제품 개발에 주력하는 바이오테크 기업으로, 나스닥 상장 요건을 모두 다시 충족했습니다. 회사는 나스닥 심리위원회(Nasdaq Hearings Panel) 심리 고문으로부터 2025년 8월 13일에 최저 입찰가 요건(Nasdaq Listing Rule 5550(a)(2)) 준수를 공식 확인받았습니다.
이번 확인은 2025년 7월 9일 나스닥 심리위원회의 결정에서 제시된 모든 조건을 충족합니다. 이에 따라 Polyrizon은 상장을 유지하며 Nasdaq Capital Market에서 "PLRZ" 티커로 계속 거래됩니다.
Polyrizon (Nasdaq: PLRZ), une entreprise de biotechnologie spécialisée dans le développement de produits intranasaux, a de nouveau satisfait à l'ensemble des exigences de cotation du Nasdaq. La société a reçu la confirmation formelle du conseiller aux auditions du Nasdaq Hearings Panel le 13 août 2025, confirmant le respect de l'exigence de prix d'enchère minimum prévue par la Nasdaq Listing Rule 5550(a)(2).
Cette confirmation répond à toutes les conditions précédemment énoncées par le Nasdaq Hearings Panel dans sa décision du 9 juillet 2025. En conséquence, Polyrizon conservera sa cotation et continuera d'être négociée sur le Nasdaq Capital Market sous le symbole "PLRZ".
Polyrizon (Nasdaq: PLRZ), ein Biotechnologieunternehmen mit Schwerpunkt auf intranasalen Produkten, hat die Einhaltung aller Nasdaq-Listungsanforderungen erfolgreich wiederhergestellt. Das Unternehmen erhielt am 13. August 2025 eine formelle Bestätigung vom Hearings Advisor des Nasdaq Hearings Panel, dass es die Anforderung bezüglich des Mindestgebotspreises nach der Nasdaq Listing Rule 5550(a)(2) erfüllt.
Die Bestätigung erfüllt alle zuvor vom Nasdaq Hearings Panel in seiner Entscheidung vom 9. Juli 2025 aufgeführten Auflagen. Daher wird Polyrizon an der Nasdaq Capital Market gelistet bleiben und weiterhin unter dem Ticker-Symbol "PLRZ" gehandelt.
- Company has regained full compliance with Nasdaq listing requirements
- Maintained listing on Nasdaq Capital Market, avoiding potential delisting
- Previous non-compliance with Nasdaq minimum bid price requirements indicates historical stock price weakness
Ra’anana, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced that it has received formal confirmation from the Hearings Advisor (the “Hearings Advisor”) of the Office of the General Counsel of the Nasdaq Hearings Panel (the “Nasdaq Hearings Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with all applicable listing requirements.
In a letter dated August 13, 2025, the Hearings Advisor informed the Company that it has demonstrated compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2) and satisfied the conditions of the Nasdaq Hearings Panel’s decision dated July 9, 2025.
This confirmation satisfies all conditions previously outlined by the Nasdaq Hearings Panel, and Polyrizon will continue to trade on the Nasdaq Capital Market under the ticker symbol “PLRZ.”
About Polyrizon
Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please visit https://polyrizon-biotech.com.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report filed with the SEC on March 11, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.
Contacts:
Michal Efraty
Investor Relations
FAQ
Has Polyrizon (PLRZ) regained Nasdaq compliance in 2025?
What was the specific Nasdaq requirement Polyrizon (PLRZ) needed to meet?
Will Polyrizon (PLRZ) continue trading on Nasdaq?
When did the Nasdaq Hearings Panel make their initial decision regarding Polyrizon?
